Table 3.

The sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy of H4, CA125, and ROMA according to menopausal status.

Group	Diagnostic test	Sensitivity (%) (95% CI)	Specificity (%) (95% CI)	Positive predictive value (%) (95% CI)	Negative predictive value (%) (95% CI)	Diagnostic accuracy (%) (95% CI)
Whole group (n = 302)	HE4	70% (61%–79%)	92.5% (89.2%–95.7%)	78.7% (70.1%–87.2%)	88.6% (84.8%–92.4%)	86.1% (82.5%–89.7%)
	CA125	82% (71.4%–92.6%)	68.3% (62.5%–74%)	33.9% (25.5%–42.3%)	95% (91.9%–98.2%)	70.5% (65.4%–75.7%)
	ROMA	80% (68.9%–91.1%)	82.5% (77.9%–87.2%)	47.6% (36.9%–58.3%)	95.4% (92.6%–98.2%)	82.1% (77.8%–86.4%)
Premenopausal subgroup (n = 188)	HE4	70% (41.6%–98.4%)	92.7% (88.9%–96.5%)	35% (14.1%–55.9%)	98.2% (96.2%–100%)	91.5% (87.5%–95.5%)
	CA125	80% (55.2%–100%)	62.4% (55.2%–69.5%)	10.7% (3.7%–17.7%)	98.2% (95.8%–100%)	63.3% (56.4%–70.2%)
	ROMA	70% (41.6%–98.4%)	82% (76.4%–87.7%)	17.9% (5.9%–30%)	98% (95.7%–100%)	81.4% (75.8%–86.9%)
Postmenopausal subgroup (n = 114)	HE4	70% (55.8%–84.2%)	91.9% (85.7%–98.1%)	82.4% (69.5%–95.2%)	85% (77.2%–92.8%)	84.2% (77.5%–90.9%)
	CA125	82.5% (70.7%–94.3%)	82.4% (73.8%–91.1%)	71.7% (58.7%–84.8%)	89.7% (82.5%–96.9%)	82.5% (75.5%–89.4%)
	ROMA	82.5% (70.7%–94.3%)	83.8% (75.4%–92.2%)	73.3% (60.4%–86.3%)	89.9% (82.7%–97%)	83.3% (76.5%–90.2%)

CI: confidence interval; ROMA: Risk of Ovarian Malignancy Algorithm.